Mobilization without immune depletion fails to restore immunological tolerance or preserve beta cell function in recent onset type 1 diabetes

Clinical and Experimental Immunology

Volumn 183, Issue 3, 2016, Pages 350-357

  Haller, M J ^a   Atkinson, M A ^a,b   Wasserfall, C H ^b   Brusko, T M ^b   Mathews, C E ^b   Hulme, M ^c   Cintron, M ^a   Shuster, J ^a   Mcgrail, K ^b   Posgai, A ^b   Schatz, D ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c J Crayton Pruitt Family Department of Biomedical Engineering   (United States)

Author keywords

Clinical trial; Granulocyte colony stimulating factor; Human; Monotherapy; Type 1 diabetes

Indexed keywords

C PEPTIDE; CD45RA ANTIGEN; CD45RO ANTIGEN; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN A1C; INSULIN; PEGFILGRASTIM; PLACEBO; GLYCOSYLATED HEMOGLOBIN; MACROGOL DERIVATIVE; PEGYLATED GRANULOCYTE COLONY-STIMULATING FACTOR; RECOMBINANT PROTEIN;

ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; BLOOD CELL COUNT; BONE PAIN; CD4 CD8 RATIO; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FEMALE; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMMOBILIZED CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; INSULIN DEPENDENT DIABETES MELLITUS; LEUKOCYTE COUNT; LEUKOCYTOSIS; LYMPHOCYTE COUNT; MALE; MEMORY T LYMPHOCYTE; MONOTHERAPY; NEUTROPHIL COUNT; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REGULATORY T LYMPHOCYTE; SINGLE BLIND PROCEDURE; SPLENOMEGALY; TREATMENT DURATION; ADULT; BLOOD; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 1; DISEASE COURSE; DRUG ADMINISTRATION; DRUG EFFECTS; IMMUNOLOGY; LYMPHOCYTE DEPLETION; MIDDLE AGED; NEUTROPHIL; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL; PHYSIOLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; C-PEPTIDE; CD4-CD8 RATIO; CHILD; DIABETES MELLITUS, TYPE 1; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; IMMUNE TOLERANCE; INSULIN; INSULIN-SECRETING CELLS; LEUKOCYTE COUNT; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; NEUTROPHILS; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; SPLENOMEGALY; T-LYMPHOCYTES, REGULATORY; YOUNG ADULT;

EID: 84958859574     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12731     Document Type: Article

References (32)

1. Atkinson MA, von Herrath M, Powers AC, Clare-Salzler M. Current concepts on the pathogenesis of type 1 diabetes - considerations for attempts to prevent and reverse the disease. Diabetes Care 2015; 38:979-88.
2. Unger J, Parkin C. Hypoglycemia in insulin-treated diabetes: a case for increased vigilance. Postgrad Med 2011; 123:81-91.
3. Tao B, Pietropaolo M, Atkinson M, Schatz D, Taylor D. Estimating the cost of type 1 diabetes in the U.S.: a propensity score matching method. PLOS ONE 2010; 5:e11501.
4. Ben Nasr M, D'Addio F, Usuelli V, Tezza S, Abdi R, Fiorina P. The rise, fall, and resurgence of immunotherapy in type 1 diabetes. Pharmacol Res 2015; 98:31-8.
5. Ferraro F, Lymperi S, Mendez-Ferrer S et al. Diabetes impairs hematopoietic stem cell mobilization by altering niche function. Sci Transl Med 2011; 3:104ra101.
6. Fadini GP, Albiero M, Vigili de Kreutzenberg S et al. Diabetes impairs stem cell and proangiogenic cell mobilization in humans. Diabetes Care 2013; 36:943-9.
7. Albiero M, Poncina N, Tjwa M et al. Diabetes causes bone marrow autonomic neuropathy and impairs stem cell mobilization via dysregulated p66Shc and Sirt1. Diabetes 2014; 63:1353-65.
8. Bendall LJ, Bradstock KF. GCSF: from granulopoietic stimulant to bone marrow stem cell mobilizing agent. Cytokine Growth Factor Rev 2014; 25:355-67.
9. Sivakumar R, Atkinson MA, Mathews CE, Morel L. GCSF: a friend or foe? Immunome Res 2015; S2:007. doi: 10.4172/1745-7580.S2.007
10. Rutella S. Granulocyte colony-stimulating factor for the induction of T-cell tolerance. Transplantation 2007; 84:S26-30.
11. Rutella S, Bonanno G, Pierelli L et al. Granulocyte colony-stimulating factor promotes the generation of regulatory DC through induction of IL-10 and IFN-alpha. Eur J Immunol 2004; 34:1291-302.
12. Kared H, Masson A, Adle-Biassette H, Bach JF, Chatenoud L, Zavala F. Treatment with granulocyte colony-stimulating factor prevents diabetes in NOD mice by recruiting plasmacytoid dendritic cells and functional CD4(+)CD25(+) regulatory T-cells. Diabetes 2005; 54:78-84.
13. Wang Y, Xiao Y, Zhong L et al. Increased neutrophil elastase and proteinase 3 and augmented NETosis are closely associated with β-cell autoimmunity in patients with type 1 diabetes. Diabetes 2014; 63:4239-48.
14. Semerad CL, Liu F, Gregory AD, Stumpf K, Link DC. GCSF is an essential regulator of neutrophil trafficking from the bone marrow to the blood. Immunity 2002; 17:413-23.
15. Couri CE, Oliveira MC, Stracieri AB et al. C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 2009; 301:1573-9.
16. Haller MJ, Gitelman SE, Gottlieb PA et al. Anti-thymocyte globulin/G-CSF treatment preserves β cell function in patients with established type 1 diabetes. J Clin Invest 2015; 125:448-55.
17. Korzenik JR, Dieckgraefe BK. An open-labelled study of granulocyte colony-stimulating factor in the treatment of active Crohn's disease. Aliment Pharmacol Ther 2005; 21:391-400.
18. Dejaco C, Lichtenberger C, Miehsler W et al. An open-label pilot study of granulocyte colony-stimulating factor for the treatment of severe endoscopic postoperative recurrence in Crohn's disease. Digestion 2003; 68:63-70.
19. Zavala F, Abad S, Ezine S, Taupin V, Masson A, Bach JF. GCSF therapy of ongoing experimental allergic encephalomyelitis via chemokine- and cytokine-based immune deviation. J Immunol 2002; 168:2011-9.
20. Snir O, Lavie G, Achiron A et al. GCSF enhances the adhesion of encephalitogenic T cells to extracellular matrix components: a possible mechanism for exacerbation of multiple sclerosis. J Neuroimmunol 2006; 172:145-55.
21. Orban T, Sosenko JM, Cuthbertson D et al. Pancreatic islet autoantibodies as predictors of type 1 diabetes in the Diabetes Prevention Trial - Type 1. Diabetes Care 2009; 32:2269-74.
22. Rahmati K, Lernmark A, Becker C et al. A comparison of serum and EDTA plasma in the measurement of glutamic acid decarboxylase autoantibodies (GADA) and autoantibodies to islet antigen-2 (IA-2A) using the RSR radioimmunoassay (RIA) and enzyme linked immunosorbent assay (ELISA) kits. Clin Lab 2008; 54:227-35.
23. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap) - a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009; 42:377-81.
24. von Vietinghoff S, Ley K. Homeostatic regulation of blood neutrophil counts. J Immunol 2008; 181:5183-8.
25. Hatzimichael E, Benetatos L, Stebbing J, Kapsali E, Panayiotopoulou S, Bourantas KL. Spontaneous splenic haematoma in a multiple myeloma patient receiving pegfilgrastim support. Clin Lab Haematol 2006; 28:416-8.
26. Snyder RL, Stringham DJ. Pegfilgrastim-induced hyperleukocytosis. Ann Pharmacother 2007; 41:1524-30.
27. Gitelman SE, Gottlieb PA, Rigby MR et al. Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol 2013; 1:306-16.
28. Bain BJ, England JM. Normal haematological values: sex difference in neutrophil count. Br Med J 1975; 1:306-9.
29. Parker MJ, Xue S, Alexander JJ et al. Immune depletion with cellular mobilization imparts immunoregulation and reverses autoimmune diabetes in nonobese diabetic mice. Diabetes 2009; 58:2277-84.
30. Xue S, Posgai A, Wasserfall C et al. Combination therapy reverses hyperglycemia in NOD mice with established type 1 diabetes. Diabetes 2015; 64:3873-84.
31. Winkler IG, Pettit AR, Raggatt LJ et al. Hematopoietic stem cell mobilizing agents G-CSF, cyclophosphamide or AMD3100 have distinct mechanisms of action on bone marrow HSC niches and bone formation. Leukemia 2012; 26:1594-601.
32. Fadini GP, Fiala M, Cappellari R et al. Diabetes limits stem cell mobilization following G-CSF but not plerixafor. Diabetes 2015; 64:2969-77.